DMD and metastatic neoplasm: Deletion was significantly associated with a decrease in DMD expression (Figure 1A) (p = 0.002), independently of gender (53.7% of men vs. 46.3% of women) (Table 2), but was significantly more frequent in metastatic tumors (Chi2 = 2.68 × 10−4; Table 2).